LegoChem Biosciences Inc (141080) - Total Liabilities

Latest as of September 2025: ₩136.37 Billion KRW ≈ $92.41 Million USD

Based on the latest financial reports, LegoChem Biosciences Inc (141080) has total liabilities worth ₩136.37 Billion KRW (≈ $92.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does LegoChem Biosciences Inc generate cash to assess how effectively this company generates cash.

LegoChem Biosciences Inc - Total Liabilities Trend (2014–2024)

This chart illustrates how LegoChem Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check 141080 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

LegoChem Biosciences Inc Competitors by Total Liabilities

The table below lists competitors of LegoChem Biosciences Inc ranked by their total liabilities.

Company Country Total Liabilities
TaTaTu SpA
PA:ALTTU
France €48.74 Million
AVIC Capital Co Ltd
SHG:600705
China CN¥376.59 Billion
Moneta Money Bank AS
PR:MONET
Czech Republic Kč472.89 Billion
Alior Bank S.A.
WAR:ALR
Poland zł87.98 Billion
Zhejiang Kaishan Compressor
SHE:300257
China CN¥10.03 Billion
JK Cement Limited
NSE:JKCEMENT
India Rs113.51 Billion
Bumrungrad Hospital PCL
BK:BH
Thailand ฿5.29 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down LegoChem Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LegoChem Biosciences Inc market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 8.97 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.25 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.19 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how LegoChem Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for LegoChem Biosciences Inc (2014–2024)

The table below shows the annual total liabilities of LegoChem Biosciences Inc from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩122.38 Billion
≈ $82.94 Million
+196.47%
2023-12-31 ₩41.28 Billion
≈ $27.98 Million
+25.35%
2022-12-31 ₩32.93 Billion
≈ $22.32 Million
-4.43%
2021-12-31 ₩34.46 Billion
≈ $23.35 Million
+44.87%
2020-12-31 ₩23.79 Billion
≈ $16.12 Million
-14.22%
2019-12-31 ₩27.73 Billion
≈ $18.79 Million
+38.49%
2018-12-31 ₩20.02 Billion
≈ $13.57 Million
-41.17%
2017-12-31 ₩34.03 Billion
≈ $23.06 Million
+15.40%
2016-12-31 ₩29.49 Billion
≈ $19.99 Million
+16.74%
2015-12-31 ₩25.26 Billion
≈ $17.12 Million
+84.24%
2014-12-31 ₩13.71 Billion
≈ $9.29 Million
--

About LegoChem Biosciences Inc

KQ:141080 Korea Biotechnology
Market Cap
$4.48 Billion
₩6.61 Trillion KRW
Market Cap Rank
#3864 Global
#102 in Korea
Share Price
₩181500.00
Change (1 day)
-1.04%
52-Week Range
₩97000.00 - ₩213500.00
All Time High
₩213500.00
About

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more